Resources-Stratified Guidelines for Classical Hodgkin Lymphoma

Relecom, Allan; Federico, Massimo; Connors, Joseph M.; Biasoli, Irène; Moccia, Alden A.; Salles, Gilles; Mckee, Thomas Alexander; Miralbell, Raymond; Borchmann, Peter; Kuruvilla, John; Johnson, Peter; Cavalli, Franco; Delavy, Martine; Dietrich, Pierre‐Yves; Flahault, Antoine

doi:10.3390/ijerph17051783

Cited by 9 publications

(11 citation statements)

References 72 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone marrow (BM) involvement is infrequent [7]. Correlation with EBV infection shows contrasting rates, ranging from 90-100% in Latin America, Africa, and Asia, to up to 50% in Western Europe and North America [8]. Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) polychemotherapy and radiotherapy are the standard treatments for cHL [1,7,8] supported by autologous hematopoietic stem cell transplantation in at least 50% of patients [1].…”

Section: Introductionmentioning

confidence: 99%

Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma

et al. 2020

View full text Add to dashboard Cite

Reed–Sternberg cells (RSCs) are hallmarks of classic Hodgkin lymphoma (cHL). However, cells with a similar morphology and immunophenotype, so-called Reed–Sternberg-like cells (RSLCs), are occasionally seen in both B cell and T cell non-Hodgkin Lymphomas (NHLs). In NHLs, RSLCs are usually present as scattered elements or in small clusters, and the typical background microenviroment of cHL is usually absent. Nevertheless, in NHLs, the phenotype of RSLCs is very similar to typical RSCs, staining positive for CD30 and EBV, and often for B cell lineage markers, and negative for CD45/LCA. Due to different therapeutic approaches and prognostication, it is mandatory to distinguish between cHL and NHLs. Herein, NHL types in which RSLCs can be detected along with clinicopathological correlation are described. Moreover, the main helpful clues in the differential diagnosis with cHL are summarized.

show abstract

Section: Introductionmentioning

confidence: 99%

Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Hodgkin lymphoma is a highly curable disease by current treatment standards. It implies access to diagnostic and treatment modalities that may not be available in settings with restricted health care resources [ 39 ]. A good score on this indicator therefore directly measures access to quality care.…”

Section: Discussionmentioning

confidence: 99%

A multidimensional framework for rating health system performance and sustainability: A nine plus one ranking system

Müller

Oakley²,

Saad

et al. 2021

J Glob Health

Self Cite

View full text Add to dashboard Cite

Background Health Care provision in terms of prevention, detection and treatment is primarily dependent on the quality of the hosting Health System. In its health report 2000, the WHO's attempt to assess and rank health systems’ quality Worldwide was heavily criticized. We propose a novel framework for health system performance and ranking using three indicators for three domains; general health system performance, clinical outcome of treatment applied to the main causes of death and health system sustainability domains. Methods Each domain was rated as “A – high”, “B – intermediate” or “C – poor” according to the aggregate score values of its three indicators. Hence the highest rank a health system can achieve is “AAA” and the lowest is “CCC”. If there is a need to define a “numerical rank” to further differentiate health systems with similar rating from one another, the total health expenditure per capita per year was used as an additional “number 10” indicator to achieve that level of differentiation. The framework was applied to Health Systems serving most of the World population including China, India, Brazil, USA, Russia, Germany, Japan, UK, France, Singapore and Switzerland. Data pertinent to each indicator was captured from published reports in peer-reviewed journals and/or from official websites. A Delphi survey was conducted for data not available online. Results Among the 11 health systems tested, no one scored AAA, Switzerland, France, Germany and Japan scored AAB, Singapore scored ABB, UK scored BBB, USA, Russia and China scored BBC, Brazil scored BCC while India scored CCC. Total health expenditure per capita per year lead to ranking Switzerland first followed by France, Germany, and Japan. Conclusion This novel ranking system is a practical and an applicable tool that test health system performance and sustainability. It can be utilized to guide all organizations, people and actions whose primary intent is to promote, restore or maintain health to achieve their targets. An International Health System Ranking database that will be hosted by the Institute of Global, Health, Faculty of Medicine, University of Geneva, Switzerland.

show abstract

“…3 PET-adapted therapies can be challenging to implement when timely access, interpretation, and reimbursement of PET/CT scans are limited. 11 We surveyed oncologists who treat patients with cHL as part of CONNECT (Classic Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment), which is, to our knowledge, the first real-world survey of physicians, patients, and caregivers about cHL, to understand their treatment decision-making process and how PET/CT scan utilization and interpretation, and barriers to PET/CT scan access, reimbursement, and comprehension, influence treatment choices.…”

Section: Survey Recruitmentmentioning

confidence: 99%

Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography–Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study

Parsons

Liu

et al. 2023

JCO Oncology Practice

View full text Add to dashboard Cite

PURPOSE We surveyed oncologists who treat classic Hodgkin lymphoma (cHL) as part of the CONNECT study to understand the treatment decision‐making process, including the impact of positron emission tomography/computed tomography (PET/CT) imaging. METHODS US physicians self-identifying as oncologists, hematologists, or hematologists/oncologists with ≥2 years of practice experience who treated ≥1 adult with stage III/IV cHL in the frontline setting in the last year were surveyed (October 19-November 16, 2020). Physician demographics, guideline adherence, and PET/CT utilization, interpretation, and access barriers were assessed. RESULTS In total, 301 physicians participated in the survey. Eighty-eight percent of physicians gave somewhat-to-significant consideration to NCCN guidelines. Most physicians (94%; n = 284) reported obtaining a PET/CT scan at diagnosis; of these physicians, 97% reported obtaining an interim PET/CT scan for stage III/IV cHL, with 65% typically obtaining an interim PET/CT scan after cycle 2. The Deauville 5-point scale (5PS) was the primary scoring system used to review PET/CT results by 62% of physicians, with a positive score defined as ≥3 by 44%, ≥4 by 37%, and ≥2 by 12% of physicians. Fifty-five percent of physicians reported difficulty in obtaining PET/CT scans. CONCLUSION Although most physicians considered NCCN guidelines when treating patients with stage III/IV cHL, interim PET/CT scans after cycle 2 were not universally obtained. When PET/CT scans were obtained, Deauville 5PS scores were not always provided, and variability existed on what defined a positive score. These findings suggest that opportunities exist for education and improved PET-adapted treatment approaches.

show abstract

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma

Cited by 9 publications

References 72 publications

Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma

Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma

A multidimensional framework for rating health system performance and sustainability: A nine plus one ranking system

Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography–Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study

Contact Info

Product

Resources

About